Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance

PFIZER INC

2026-Q1 EPS reported $0.47 revenue$14,451,000,000

Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.
Reported diluted EPS $0.47, adjusted $0.75 vs $0.92 in Q1 '25 (-18%).
Reaffirmed FY26 revenue guidance $59.5-62.5B and adj EPS $2.80-3.00.
Positive Phase 3 readouts for Elrexfio (RRMM), Padcev (MIBC), Talzenna+Xtandi, Lyme vaccine 73-75% efficacy.
Exited ViiV Healthcare for $1.875B; Vyndamax patent settlement extends to 2031; GLP-1 collaboration in China for ecnoglutide.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported the first quarter of 2026 results: revenue $14,451, net income 2,687, EPS 0.47. Guidance reaffirmed.

Period: the first quarter of 2026
Revenue: $14,451
Net income: 2,687
EPS: 0.47
Guidance: reaffirmed
Result: reported results

Exact text from the filing

rates (5) . Results for the first quarter of 2026 and 2025 (6) are summarized below. ($ in millions, except per share amounts) First-Quarter 2026 2025 % Change Revenues $ 14,451 $ 13,715 5% Reported (3) Net Income 2,687 2,967 (9%) Reported (3) Diluted EPS 0.47 0.52 (10%) Adjusted (4) Income 4,290 5,237 (18%) Adjusted (4) Diluted EPS 0.75 0.92 (18%)

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-26-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.